Navigation Links
New Research from Best Practices, LLC can Improve Formulary Access and Product Placement for Biopharma Companies: Managed Markets Market Research
Date:2/18/2010

CHAPEL HILL, N.C., Feb. 18 /PRNewswire/ -- Companies invest hundreds of millions – and occasionally billions – of dollars overall in developing new drugs and face countless hurdles in bringing these new products to market.  To make good on these vast investments, successful companies must maximize product uptake across all customer groups: not only among patients and physicians, but also among government and private payers to win formulary access and improve product placement.  

In fact, these payer groups, who represent millions of individual consumers, compose biopharma's largest revenue base and earning a favorable formulary tier position with a single large carrier can open the door to hundreds of millions in potential revenue.

Companies face two main problems in gaining traction with large payer groups. First, since the market for most therapeutic areas and medical conditions is already crowded with similar treatments, companies must to be able to articulate a clear medical or economic advantage for their products.  Second, companies often struggle to gain access to key decision makers within the Managed Markets organization.

By anticipating payer attitudes and behavior early on in the product lifecycle, a high-functioning Managed Markets market research group can prove invaluable in setting clinical and commercial strategy.  In addition, savvy Managed Markets market research groups also provide vital insight and value by delivering reliable and actionable knowledge of the ever evolving Managed Markets landscape.  

A new benchmarking study from Best Practices, LLC,

SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
2. IPA Helps Researchers Utilize and Share Current Disease Knowledge Through New Dynamic Reporting Capability
3. Dutch Public-Private Partnership Invests 28 Million Euro on Research Into Personalized Medicine
4. US HIFU Partners with Riverside Research Institute to Add Cancer Targeting Technology to HIFU Treatment
5. Infosys Technologies and Elan Pharmaceuticals Apply Co-creation Model to Transform Discovery Research
6. Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals
7. New Research Gives Insight to the Frequency of Doctor Shopping Occurring Within Prescription Monitoring Programs
8. Medical Research Council Technologys Centre for Therapeutics Discovery Opens its First Call For Targets in an Effort to Develop Drugs in Areas of Serious Unmet Need
9. Americas Pharmaceutical Research Companies Donate $35 Million to Relief Efforts in Haiti; More Help Coming
10. ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report
11. Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... N.Y. , March 4, 2015  Kannalife Sciences, ... MD has joined its Scientific Advisory Board to assist ... development efforts towards the use of cannabinoid therapeutics for ... is the forensic pathologist responsible for conducting the full ... Hall of Fame center for the Pittsburgh Steelers. It ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Negative Pressure Wound Therapy Market ... Industry Analysis, Size, Share, Growth, Trends and Forecast ... , The global negative pressure ... and by geography. By product types the NPWT ...
(Date:3/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... the upcoming 27 th Annual ROTH Conference, taking ... CA.  Dr. Michael Berelowitz , Chairman ... a corporate overview on March 10, 2015. ...
Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3
... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively.  Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...
... Merz Pharmaceuticals, LLC, today announced that data from ... Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from ... will be presented at the 115th Annual Meeting of ... These data include an extension of the ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 2Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 4Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 5Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 6Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 7Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 8
(Date:3/4/2015)... (PRWEB) March 04, 2015 Starting February ... LASIK and PRK procedures at their new location in ... Dr. Joseph King and Dr. Gabriel Chu also provide ... in Surrey is named Fraser Valley Cataract and Laser ... accredited by the College of Physicians and Surgeons of ...
(Date:3/4/2015)... Alliance Healthcare Foundation (AHF), a non-profit organization working ... in San Diego and Imperial Counties, announced today that ... Grants program with awards totaling $1 million. , ... Support Grants program. Grant recipients were chosen through a ... committee, as well as the community as a whole. ...
(Date:3/4/2015)... " Optrix by Body Glove ” ... Tech Report, which takes a look at the latest ... Scott Steinberg, a special reporter for NewsWatch and a ... viewers how they have an ultra-rugged, waterproof case with ... a major player at the Consumer Electronics Show in ...
(Date:3/4/2015)... As seen on Advanced Fertility Center ... a painful condition in which the lining of the ... leading to very unpleasant symptoms and complications that greatly ... terrible effect on women’s quality of life due to ... cause of infertility in women and carries a huge ...
(Date:3/4/2015)... 04, 2015 The New Mel Brooks ... music, will be performed by the award-winning Drama Department ... this March 6-22, 2015, on Fridays, Saturdays and Sundays. ... High School (27118 Silver Spur Road, Rolling Hills ... the program or may be purchased on-line at ...
Breaking Medicine News(10 mins):Health News:King LASIK relocates to Surrey, British Columbia 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 3Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2
... the brain illness in cattle months before symptoms appear, ... A simple, inexpensive DNA blood test may be able ... before they show any clinical signs of the disease, ... BSE (bovine spongiform encephalopathy) can only be diagnosed by ...
... (BRONX, NY) Men who develop prostate cancer face an ... a so-called breast cancer gene mutation, scientists from the Albert ... issue of Clinical Cancer Research . The findings could ... treatment options. , The study, involving 979 men with ...
... DIEGO, Jan. 29 Amylin Pharmaceuticals, Inc. (Nasdaq: ... an amended 13-D filing with the Securities and Exchange ... funds announcing their intent to nominate a slate of ... 2009 annual meeting. Amylin has not yet received the ...
... to improve physical function, decrease symptoms and minimize ... pain. Numerous randomized trials and clinical practice guidelines ... individually tailored, supervised exercise programs are associated with ... a lack of knowledge about exercise prescription, including ...
... North State Bancorp (OTC,Bulletin Board: NSBC) (the "Company"), ... of $687.6 million as of December 31, 2008,compared to ... an increase,of $140.1 million or 25.6%. , ... December 31, 2008 were $612.7,million and total loans were ...
... AnnouncedPITTSBURGH, Jan. 29 invivodata inc., the ... (ePRO) solutions and services for global clinical ... 2009 -- its annual Patient Reported Outcomes ... http://www.invivodata.com/epro2009 to register for the ...
Cached Medicine News:Health News:Blood Test for 'Mad Cow' Disease May Be Near 2Health News:Gene mutations increase risk for aggressive prostate cancer 2Health News:Gene mutations increase risk for aggressive prostate cancer 3Health News:Exercise underutilized for chronic back and neck pain 2Health News:Exercise underutilized for chronic back and neck pain 3Health News:North State Bancorp Reports Profitable 2008 2Health News:North State Bancorp Reports Profitable 2008 3Health News:North State Bancorp Reports Profitable 2008 4Health News:North State Bancorp Reports Profitable 2008 5Health News:North State Bancorp Reports Profitable 2008 6Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 2Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: